Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management

Oncologist

Volumn 13, Issue 8, 2008, Pages 838-844

  Guarneri, Valentina ^a   Giovannelli, Simona ^a   Ficarra, Guido ^a   Bettelli, Stefania ^a   Maiorana, Antonino ^a   Piacentini, Federico ^a   Barbieri, Elena ^a   Dieci, Maria Vittoria ^a   D'Amico, Roberto ^a   Jovic, Gordana ^a   Conte, Pierfranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Breast cancer; HER 2; Hormone receptors; Metastasis biopsy; Primary tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; COLON METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; PATIENT CARE; PERITONEUM METASTASIS; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE METASTASIS; STOMACH METASTASIS; TUMOR BIOPSY; VISCERAL METASTASIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 50649119930     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0048     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717.
2. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;l20:719-726.
3. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30:259-265.
4. Shimizu C, Fukutomi T, Tsuda H et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20.
5. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 2001;61:5345-5348.
6. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
7. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-2173.
8. Edgerton SM, Moore D 2nd, Merkel D et al. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-221.
9. Regitnig P, Schippinger W, Lindbauer M et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-926.
10. Zidan J, Dashkovsky I, Stayerman C et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-556.
11. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-1769.
12. Vincent-Salomon A, Pierga JY, Couturier J et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: A possible tool for anti-HER2 therapy management? Br J Cancer 2007;96:654-659.
13. Santinelli A, Pisa E, Stramazzotti D et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999-1004.
14. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2008 Feb 14 [Epub ahead of print].
15. Wilking U, Skoog L, Elmberger G et al. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients. J Clin Oncol 2007;25(18 suppl): Abstract 1023.
16. Broom RJ, Tang P, Simmons C et al. Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples. J Clin Oncol 2007;25(18 suppl): Abstract 1024.
17. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-485.
18. Li BD, Byskosh A, Molteni A et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994;57:71-77.
19. Kuukasjarvi T, Kononen J, Helin H et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-2589.
20. Spataro V, Price K, Goldhirsch A et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-740.
21. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005;12:10-19.
22. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
23. Pertschuk LP, Axiotis CA, Feldman JG et al. Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999;5:369-374.
24. Kerbel RS. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects. Adv Cancer Res 1990;55:87-132.
25. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V. 2.2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed July 10, 2008.